NEPHROS INC
Close on Oct 19, 2026
- Market cap
- $40.89M
- P/E (TTM)
- 23.0
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $6.00M | $0.11 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $5.21M | $0.01 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | $4.40M | $0.02 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $4.90M | $0.05 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 6, 2025 | After market close | $3.90M | $0.03 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | After market close | $3.50M | $0.02 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 7, 2024 | After market close | $3.30M | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 9, 2023 | After market close | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | Apr 4, 2023 | After market close | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Jan 11, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Oct 11, 2022 | Before market open | – | – | – |
Press releases
Announcements Nephros filed with the SEC
Announces Date for 2026 Annual Meeting of Stockholders
Other events · EX-99.1 to Form 8-K
Announces Strong Financial Results for Quarter Ended June 30, 2026
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Financial Results for Quarter Ended March 31, 2026
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Strong Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Announces Financial Results for Quarter Ended March 31, 2025
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Fourth Quarter and Fiscal Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Announces Financial Results for Quarter Ended September 30, 2024
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Financial Results for Quarter Ended March 31, 2024
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Fourth Quarter and Fiscal Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Announces Results for Quarter Ended June 30, 2023
Results of operations · EX-99.1 to Form 8-K
Announces Preliminary Results for First Quarter 2023
Results of operations · EX-99.1 to Form 8-K
Announces Fourth Quarter and Fiscal Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Announces Preliminary Results for Fourth Quarter and Fiscal Year 2022
Results of operations · EX-99.1 to Form 8-K
Announces Results for Quarter Ended September 30, 2022
Results of operations · EX-99.1 to Form 8-K
Announces Agreement to Sell Pathogen Detection Systems Business and
Material agreement · Results of operations · EX-99.1 to Form 8-K
Announces Results for Quarter Ended June 30, 2022
Results of operations · EX-99.1 to Form 8-K
Announces Preliminary Results for Quarter Ended June 30, 2022 and
Results of operations · EX-99.1 to Form 8-K
Receives FDA 510(k) Clearance for HDF Assist Module
Other events · EX-99.1 to Form 8-K